近日,康希诺发布2024年财报。披露公司去年营收增长137.01%至8.46亿元。净亏损3.79亿元。报告期内,公司工作重点主要为推进流脑结合疫苗的商业化进程及非新冠疫苗产品的研发。疫苗商业化端,公司持续搭建销售渠道,ACYW135 群脑膜炎球菌多糖结合疫苗(CRM197 载体)曼海欣®作为中国市场上唯一的四价流脑结合疫苗,市场占有率不断提升,同时公司经营受全球公共卫生事件的影响已经基本消除。因此...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.